BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22170434)

  • 1. Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker.
    Hao Z; Zhang H; Cowell J
    Tumour Biol; 2012 Jun; 33(3):723-30. PubMed ID: 22170434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker.
    Xie C; Powell C; Yao M; Wu J; Dong Q
    Int J Biochem Cell Biol; 2014 Feb; 47():113-7. PubMed ID: 24361302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E2 Ubiquitin-conjugating Enzyme, UBE2C Gene, Is Reciprocally Regulated by Wild-type and Gain-of-Function Mutant p53.
    Bajaj S; Alam SK; Roy KS; Datta A; Nath S; Roychoudhury S
    J Biol Chem; 2016 Jul; 291(27):14231-14247. PubMed ID: 27129209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UBE2C promotes the progression of head and neck squamous cell carcinoma.
    Jin Z; Zhao X; Cui L; Xu X; Zhao Y; Younai F; Messadi D; Hu S
    Biochem Biophys Res Commun; 2020 Mar; 523(2):389-397. PubMed ID: 31870550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma.
    Wang X; Yin L; Yang L; Zheng Y; Liu S; Yang J; Cui H; Wang H
    FEBS J; 2019 Dec; 286(24):4889-4909. PubMed ID: 31715067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UBE2C is overexpressed in ESCC tissues and its abrogation attenuates the malignant phenotype of ESCC cell lines.
    Palumbo A; Da Costa NM; De Martino M; Sepe R; Pellecchia S; de Sousa VP; Nicolau Neto P; Kruel CD; Bergman A; Nasciutti LE; Fusco A; Pinto LF
    Oncotarget; 2016 Oct; 7(40):65876-65887. PubMed ID: 27588470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression.
    Shen Z; Jiang X; Zeng C; Zheng S; Luo B; Zeng Y; Ding R; Jiang H; He Q; Guo J; Jie W
    BMC Cancer; 2013 Apr; 13():192. PubMed ID: 23587173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.
    Kariri Y; Toss MS; Alsaleem M; Elsharawy KA; Joseph C; Mongan NP; Green AR; Rakha EA
    Breast Cancer Res Treat; 2022 Apr; 192(3):529-539. PubMed ID: 35124721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
    Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
    [No Abstract]   [Full Text] [Related]  

  • 10. Pan-Cancer Analyses of the Tumor Microenvironment Reveal That Ubiquitin-Conjugating Enzyme E2C Might Be a Potential Immunotherapy Target.
    Huang GZ; Chen ZQ; Wu J; Shao TR; Zou C; Ai YL; Lv XZ
    J Immunol Res; 2021; 2021():9250207. PubMed ID: 34950739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions.
    Chou CP; Huang NC; Jhuang SJ; Pan HB; Peng NJ; Cheng JT; Chen CF; Chen JJ; Chang TH
    PLoS One; 2014; 9(4):e93934. PubMed ID: 24699941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis.
    Li R; Pang XF; Huang ZG; Yang LH; Peng ZG; Ma J; He RQ
    BMC Cancer; 2021 Sep; 21(1):996. PubMed ID: 34488675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma.
    Bavi P; Uddin S; Ahmed M; Jehan Z; Bu R; Abubaker J; Sultana M; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Prabhakaran S; Hussain AR; Al-Kuraya KS
    Am J Pathol; 2011 May; 178(5):2109-20. PubMed ID: 21514426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma.
    Lin J; Raoof DA; Wang Z; Lin MY; Thomas DG; Greenson JK; Giordano TJ; Orringer MB; Chang AC; Beer DG; Lin L
    Neoplasia; 2006 Dec; 8(12):1062-71. PubMed ID: 17217624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of UBE2C in Brain Cancer Invasion and Dissemination.
    Domentean S; Paisana E; Cascão R; Faria CC
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ubiquitin-conjugating enzyme 2C on invasion, proliferation and cell cycling of lung cancer cells.
    Tang XK; Wang KJ; Tang YK; Chen L
    Asian Pac J Cancer Prev; 2014; 15(7):3005-9. PubMed ID: 24815438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UBE2C induces EMT through Wnt/β‑catenin and PI3K/Akt signaling pathways by regulating phosphorylation levels of Aurora-A.
    Wang R; Song Y; Liu X; Wang Q; Wang Y; Li L; Kang C; Zhang Q
    Int J Oncol; 2017 Apr; 50(4):1116-1126. PubMed ID: 28260026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation between the expression of ubiquitin-conjugating enzyme 2C and prostate cancer prognosis.
    Kim JH; Lee KW; Yang HJ; Park JJ; Lee CH; Jeon YS; Yun JH; Park S; Song SJ; Kim YH; Lee JH; Moon A; Song YS
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6351-6360. PubMed ID: 36752909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of UBE2C as hub gene in driving prostate cancer by integrated bioinformatics analysis.
    Wang Y; Wang J; Tang Q; Ren G
    PLoS One; 2021; 16(2):e0247827. PubMed ID: 33630978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.
    Martínez-Canales S; López de Rodas M; Nuncia-Cantarero M; Páez R; Amir E; Győrffy B; Pandiella A; Galán-Moya EM; Ocaña A
    Cancer Med; 2018 May; 7(5):1896-1907. PubMed ID: 29575713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.